Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer Acute toxicity of 12C for PC

Acta Oncologica

Volumn 50, Issue 6, 2011, Pages 784-790

  Nikoghosyan, Anna V ^a   Schulz Ertner, Daniela ^b   Herfarth, Klaus ^a   Didinger, Bernd ^a   Münter, Marc W ^a   Jensen, Alexandra D ^a   Jäkel, Oliver ^c,d   Hoess, Angelika ^d   Haberer, Thomas ^d   Debus, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CARBON;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DYSURIA; FEASIBILITY STUDY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; NOCTURIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; SALVAGE THERAPY; TENESMUS;

ACUTE DISEASE; AGED; CARBON; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; PHOTONS; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79960551820     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.584558     Document Type: Article

References (24)

1. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, et al. Long-term failure patterns and survival in a rand-omized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011;79:1310-7.
2. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999;85:2460-8. (Pubitemid 29244857)
3. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6. (Pubitemid 34787844)
4. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for local-ized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330-7.
5. Rossi CJ. Conformal proton beam therapy of prostate cancer-update on the Loma Linda University medical center experience. Strahlenther Onkol 1999;175(Suppl 2): 82-4. (Pubitemid 29533461)
6. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11.
7. Akakura K, Tsujii H, Morita S, Tsuji H, Yagishita T, Isaka S, et al. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 2004;58:252-8. (Pubitemid 38168922)
8. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe JE, Kanai T, et al. Carbon ion radiation therapy for prostate can-cer: Results of a prospective phase II study. Radiother Oncol 2006;81:57-64. (Pubitemid 44512056)
9. Haberer T, Becher W, Schardt D, Kraft G. Magnetic scan-ning system for heavy ion therapy. Nucl Instr Meth Phys Res 1993;330:296-305.
10. Krämer M, J ä kel O, Haberer T, Rietzel E, Schardt D, Scholz M, et al Treatment planning for scanned ion beams. Radiother Oncol 2004 73(Suppl 2):S80-5.
11. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trial 1989;10:1-10. (Pubitemid 19099520)
12. Herfarth KK, Pirzkall A, Lohr F, Schulz-Ertner D, Spoo J, Frank C, et al. First experiences with a noninvasive patient set-up system for radiotherapy of the prostate. Strahlenther Onkol 2000;176:217-22. (Pubitemid 30313637)
13. Kraft G. RBE and its interpretation. Strahlenther Onkol 1999;175(Suppl II):44-7. (Pubitemid 29533451)
14. Preiser K, Bortfeld T, Hartwig K, Schlegel W, Stein J. Inverse radiotherapy planning for intensity modulated photon fi elds. Radiologe 1998;38:228-34. (Pubitemid 28157050)
15. Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, et al. The Phoenix defi nition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2008;112:55-60.
16. Matzinger O, Duclos F, van den Bergh A, Carrie C, Vill à S, Kitsios P, et al. EORTC Radiation Oncology Group. Acute toxicity of curative radiotherapy for intermediate-and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009;45:2825-34.
17. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxici-ties after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-9. (Pubitemid 351296130)
18. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, et al. Acute and late toxicity after dose escalation to 82 GyEGyEGyE using conformal proton radiation for localized prostate cancer: Initial Report of American College of Radiology Phase II Study 03-12. Int J Radiat Oncol Biol Phys Epub 2010 Oct 5.
19. Fowler J, Chappell R, Ritter M. Is a/ ß for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
20. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 2010;96:6-12.
21. Nikoghosyan A, Schulz-Ertner D, Didinger B, J ä kel O, Zuna I, H ö ss A, et al. Evaluation of the therapeutical potential of heavy ion therapy for patients with locally advanced pros-tate cancer. Int J Radiat Oncol Biol Phys 2004;58:89-97. (Pubitemid 38010341)
22. Thörnqvist S, Petersen JB, Høyer M, Bentzen LN, Muren LP. Propagation of target and organ at risk contours in radiotherapy of prostate cancer using deformable image registration. Acta Oncol 2010; 49: 1023-32.
23. Søvik A, Rødal J, Skogmo HK, Lervåg C, Eilertsen K, Malinen E. Adaptive radiotherapy based on contrast enhanced cone beam CT imaging. Acta Oncol 2010;49: 972-7.
24. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of pros-tate cancer. N Engl J Med 2009;360:2516-27.